FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a quinazolinone derivative of formula I, where values R1-R4, X, Z are given in the patent claim, a method for production thereof, a pharmaceutical composition and use thereof.
EFFECT: compound is intended for treating diseases, disorders or conditions associated with TNF-α.
17 cl, 5 tbl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
NEW ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION INCLUDING THEREOF AND USE THEREOF | 2018 |
|
RU2728829C1 |
ISOINDOLINE DERIVATIVE, INTERMEDIATE PRODUCT, METHOD OF PRODUCING, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2015 |
|
RU2695521C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | 2020 |
|
RU2819762C1 |
ISOINDOLINE DERIVATIVE, ITS PHARMACEUTICAL COMPOSITION AND USE | 2021 |
|
RU2809680C1 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | 2015 |
|
RU2701188C2 |
BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND ITS USE | 2020 |
|
RU2800652C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2734390C2 |
SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2013 |
|
RU2607081C2 |
Authors
Dates
2020-08-24—Published
2017-01-13—Filed